Modulation_NN
of_IN
the_DT
immune_JJ
response_NN
and_CC
tumor_NN
growth_NN
by_IN
activated_VBN
Ras_NN
._.

As_IN
a_DT
result_NN
of_IN
its_PRP$
transforming_VBG
abilities_NNS
,_,
activated_VBN
Ras_NN
is_VBZ
expressed_VBN
in_IN
a_DT
great_JJ
number_NN
of_IN
cancers_NNS
._.

The_DT
ras_NN
mutation_NN
frequency_NN
varies_VBZ
between_IN
95_CD
%_NN
in_IN
pancreatic_JJ
cancer_NN
and_CC
5_CD
%_NN
in_IN
breast_NN
cancer_NN
._.

In_IN
leukemia_NN
,_,
the_DT
highest_JJS
frequency_NN
-LRB-_-LRB-
30_CD
%_NN
-RRB-_-RRB-
is_VBZ
found_VBN
in_IN
acute_JJ
myeloid_JJ
leukemia_NN
._.

The_DT
presence_NN
of_IN
ras_NN
mutations_NNS
has_VBZ
been_VBN
correlated_VBN
with_IN
a_DT
poor_JJ
prognosis_NN
and_CC
negative_JJ
clinical_JJ
outcome_NN
._.

This_DT
suggests_VBZ
that_IN
mutated_VBN
Ras_NN
activates_VBZ
mechanisms_NNS
,_,
which_WDT
favor_VBP
tumor_NN
growth_NN
,_,
enhance_VBP
the_DT
metastatic_JJ
capacity_NN
of_IN
tumors_NNS
or_CC
modulate_VBP
tumor-specific_JJ
immune_JJ
responses_NNS
._.

Several_JJ
new_JJ
functions_NNS
of_IN
Ras_NN
,_,
such_JJ
as_IN
downregulation_NN
of_IN
major_JJ
histocompatibility_NN
complex_NN
molecules_NNS
,_,
upregulation_NN
of_IN
certain_JJ
cytokines_NNS
,_,
growth_NN
factors_NNS
and_CC
degradative_JJ
enzymes_NNS
have_VBP
been_VBN
uncovered_VBN
in_IN
the_DT
last_JJ
decade_NN
._.

Additionally_RB
,_,
mutated_VBN
Ras_NN
can_MD
also_RB
serve_VB
as_IN
a_DT
primary_JJ
target_NN
for_IN
the_DT
development_NN
of_IN
immunotherapy_NN
or_CC
drug_NN
therapy_NN
._.

This_DT
review_NN
will_MD
discuss_VB
the_DT
mechanisms_NNS
by_IN
which_WDT
Ras_NN
expressing_VBG
tumors_NNS
are_VBP
able_JJ
to_TO
evade_VB
destruction_NN
by_IN
the_DT
immune_JJ
system_NN
and_CC
enhance_VB
their_PRP$
growth_NN
and_CC
metastatic_JJ
potential_NN
._.

It_PRP
will_MD
further_RB
elaborate_VB
on_IN
the_DT
attempts_NNS
to_TO
develop_VB
successful_JJ
immunotherapy_NN
and_CC
drug_NN
therapy_NN
targeting_VBG
Ras_NN
expressing_VBG
tumors_NNS
._.

